866-364-2300 ext. 233

Center for Clinical Neuroscience

Psychiatric Medication

The Yellowbrick Center for Clinical Neuroscience (CCN) in Evanston, just north of Chicago, Illinois, is committed to providing the patients with cutting-edge, scientifically proven techniques for the diagnosis and treatment of emerging adults with complex mental health needs.

The mission of the CCN is to provide a range of scientifically-proven techniques to help those patients that have not responded, or not responded fully, to the typical approach to mental health problems.

Diagnosis is established through the use of the Structured Clinical Interview for Diagnosis, or SCID, which has been demonstrated to be the most reliable and valid method of determining psychiatric diagnosis. A convergence of other data then support the SCID in determining diagnosis, including a variety of psychometric instruments, as well as functional neuroimaging through the use of quantitative electroencephalography (qEEG).

Treatment recommendations often include medications, though a variety of non-medication based therapeutic modalities are also employed to provide the patient the highest level of support in the work of recovery from psychiatric struggle. Medication recommendation are guided by pharmacogenomic testing, a technique that allows recommendations to be based on individualized understanding of the patients metabolism and neurophysiology. Non-medication based modalities ranging from neuromodulatory techniques such as TMS and Alpha Stim to nutriceuticals (e. g. specific vitamins and minerals, Omega 3 supplementation, etc) to exercise, sleep hygiene and yoga.

Why is our treatment and philosophy unique?

In accordance with the Yellowbrick Model, the CCN approaches the mental health problems from a developmental, neurobiological perspective. Traditional psychiatric techniques are supplemented by understanding how a person’s struggles are manifesting in their brain, as well as their behavior. Therapeutic recommendations are based on a holistic understanding of the patient, informed by understanding their psychology and developmental history and, as importantly, their genetics and brain function.

Yellowbrick’s CCN places a priority emphasis on a consultative, collaborative partnership with patients and their families. Professionals provide consultative expertise assisting emerging adults in making fully informed choices regarding health and well-being.

What are concerns and positive results of psychiatric medication at Yellowbrick?

The use of pharmacogenomic testing – beginning to fulfill the promise of truly individualized medicine – allows us to understand what genetic vulnerabilities a patient may have to experiencing side effects from a given medication, or not being likely to experience intended therapeutic effects. While this technology is not yet at the point where we can tell which is the right medication, we can tell which medications are likely to be a bad choice, having a higher chance of side effects or lack of therapeutic effect. This can save patients unknown weeks and months of going the trial and error process of medication selection that characterized psychiatric practice prior to the advent of pharmacogenomics.

What are the most common needs and therapies for psychiatric medication?

Often, patients have tried one or more medications and failed to respond, respond fully, or have responded with side effects. For those patients who are not involved in the Yellowbrick Life Strategies IOP, the CCN can assist their treatment team in through a collaborative consultation. If a patient lacks a treatment team, we can assist them in finding expert care in their community.

The CCN is also able to offer non-medication modalities, such as TMS, in partnership with a patient’s current psychiatrist.

What to Expect from Treatment at the Yellowbrick CCN

A CCN consultation will involve the collection of previous medical records, conversation with current or past mental health providers, the collection of a DNA sample (done by a simple swab of the cheek), a variety of pen-and-paper and computer-based tests, several EEG-based tests, as well as an extensive psychiatric interview.

The typical CCN consult lasts 2 – 3 days, depending on the extent of the consult, number of records to review, etc. Consultations culminate in a collaboration conference in which the key findings and recommendations are discussed, so that any therapeutic recommendations can be implemented as quickly as possible. A full report of the consultation is prepared within 2-4 weeks following the consultation.

Our Specially Trained Mental Health Professionals

David H. Baron, MD, is the Senior Staff (Board Certified) Psychiatrist providing leadership, clinical and administrative oversight for the Center for Clinical Neuroscience.

Marc Sandrolini MD is a Board Certified Child and Adolescent psychiatrist with twenty years experience in academic and clinical settings working with children, teenagers and emerging adults.

Jesse Viner, MD, a Board Certified psychiatrist and psychoanalyst with four decades of experience, is the Founder and Executive Medical Director of Yellowbrick, overseeing all of the operations with Yellowbrick, including the CCN.

 

At Yellowbrick, emerging adults find their way home.

For more information, please contact Yellowbrick at 866.364.2300.